News | July 28, 2025
GSK forges $12 billion alliance with Hengrui Pharma
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
This year, 40 women students are participating, selected through a rigorous process evaluating academic merit, research interest, and socio-economic background
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
ARGX-119 is the sixth molecule developed through our Immunology Innovation Program to show proof-of-concept
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio
Subscribe To Our Newsletter & Stay Updated
